UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK; FabRx Ltd., Henwood House, Henwood, Ashford, Kent TN24 8DH, UK; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R + D Pharma Group (GI-1645), Universidade de Santiago de Compostela, 15782, Spain.
Adv Drug Deliv Rev. 2022 Mar;182:114098. doi: 10.1016/j.addr.2021.114098. Epub 2022 Jan 5.
Digitalisation of the healthcare sector promises to revolutionise patient healthcare globally. From the different technologies, virtual tools including artificial intelligence, blockchain, virtual, and augmented reality, to name but a few, are providing significant benefits to patients and the pharmaceutical sector alike, ranging from improving access to clinicians and medicines, as well as improving real-time diagnoses and treatments. Indeed, it is envisioned that such technologies will communicate together in real-time, as well as with their physical counterparts, to create a large-scale, cyber healthcare system. Despite the significant benefits that virtual-based digital health technologies can bring to patient care, a number of challenges still remain, ranging from data security to acceptance within the healthcare sector. This review provides a timely account of the benefits and challenges of virtual health interventions, as well an outlook on how such technologies can be transitioned from research-focused towards real-world healthcare and pharmaceutical applications to transform treatment pathways for patients worldwide.
医疗保健行业的数字化有望在全球范围内彻底改变患者的医疗保健。从不同的技术来看，虚拟工具，包括人工智能、区块链、虚拟现实和增强现实等，都为患者和制药行业带来了重大利益，从改善与临床医生和药物的联系，到提高实时诊断和治疗。事实上，可以预见的是，这些技术将实时相互通信，以及与物理对应物通信，以创建一个大规模的、网络医疗保健系统。尽管基于虚拟的数字健康技术可以为患者护理带来重大利益，但仍存在许多挑战，从数据安全到医疗保健部门的接受度。本综述及时说明了虚拟健康干预的益处和挑战，以及如何将这些技术从以研究为重点转变为现实世界的医疗和制药应用，从而改变全球患者的治疗途径。
